<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">World J Clin Cases</journal-id><journal-id journal-id-type="publisher-id">WJCC</journal-id><journal-title-group><journal-title>World Journal of Clinical Cases</journal-title></journal-title-group><issn pub-type="epub">2307-8960</issn><publisher><publisher-name>Baishideng Publishing Group Inc</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6819294</article-id><article-id pub-id-type="other">jWJCC.v7.i20.pg3329</article-id><article-id pub-id-type="doi">10.12998/wjcc.v7.i20.3329</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>Severe mental disorders following anti-retroviral treatment in a patient on peritoneal dialysis: A case report and literature review</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>He</surname><given-names>Qi-En</given-names></name><aff>Kidney Disease Center, the First Affiliated Hospital, College of Medicine, Zhejiang University, Key Laboratory of Kidney Disease Prevention and Control Technology, Zhejiang Province, the Third Grade Laboratory Under the National State, Administration of Traditional Chinese Medicine, Hangzhou 310000, Zhejiang Province, China</aff><aff>Department of Nephrology, Beilun People's Hospital, Ningbo 315000, Zhejiang Province, China</aff></contrib><contrib contrib-type="author"><name><surname>Xia</surname><given-names>Min</given-names></name><aff>Department of Nephrology, Beilun People's Hospital, Ningbo 315000, Zhejiang Province, China</aff></contrib><contrib contrib-type="author"><name><surname>Ying</surname><given-names>Guang-Hui</given-names></name><aff>Department of Nephrology, Beilun People's Hospital, Ningbo 315000, Zhejiang Province, China</aff></contrib><contrib contrib-type="author"><name><surname>He</surname><given-names>Xue-Lin</given-names></name><aff>Kidney Disease Center, the First Affiliated Hospital, College of Medicine, Zhejiang University, Key Laboratory of Kidney Disease Prevention and Control Technology, Zhejiang Province, the Third Grade Laboratory Under the National State, Administration of Traditional Chinese Medicine, Hangzhou 310000, Zhejiang Province, China</aff><aff>Department of Nephrology, Beilun People's Hospital, Ningbo 315000, Zhejiang Province, China</aff></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Jiang-Hua</given-names></name><aff>Kidney Disease Center, the First Affiliated Hospital, College of Medicine, Zhejiang University, Key Laboratory of Kidney Disease Prevention and Control Technology, Zhejiang Province, the Third Grade Laboratory Under the National State, Administration of Traditional Chinese Medicine, Hangzhou 310000, Zhejiang Province, China</aff></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Yi</given-names></name><aff>Kidney Disease Center, the First Affiliated Hospital, College of Medicine, Zhejiang University, Key Laboratory of Kidney Disease Prevention and Control Technology, Zhejiang Province, the Third Grade Laboratory Under the National State, Administration of Traditional Chinese Medicine, Hangzhou 310000, Zhejiang Province, China. <email>zjukidney@zju.edu.cn</email></aff></contrib></contrib-group><author-notes><fn><p>Author contributions: Yang Y performed the investigation and provided resources for the case care and report; Xia M, Ying GH collected the patient&#x02019;s clinical data; He XL analyzed data; He QE wrote the first draft of the article; Chen JH and Yang Y reviewed and edited the article for important intellectual content.</p><p>Supported by <funding-source>the grant from the National Nature Science Foundation of China</funding-source>, No. <award-id>81670621</award-id>; <funding-source>and the Nature Science Foundation of Zhejiang Province</funding-source>, No. <award-id>LY16H050001</award-id>.</p><p>Corresponding author: Yi Yang, MD, Doctor, Kidney Disease Center, the First Affiliated Hospital, College of Medicine, Zhejiang University, Key Laboratory of Kidney Disease Prevention and Control Technology, Zhejiang Province; the Third Grade Laboratory under the National State, Administration of Traditional Chinese Medicine, Hangzhou 310000, Zhejiang Province, China. <email>zjukidney@zju.edu.cn</email></p><p>Telephone:+86-571-87236992</p></fn></author-notes><pub-date pub-type="ppub"><day>26</day><month>10</month><year>2019</year></pub-date><pub-date pub-type="epub"><day>26</day><month>10</month><year>2019</year></pub-date><volume>7</volume><issue>20</issue><fpage>3329</fpage><lpage>3334</lpage><history><date date-type="received"><day>29</day><month>5</month><year>2019</year></date><date date-type="rev-recd"><day>23</day><month>8</month><year>2019</year></date><date date-type="accepted"><day>11</day><month>9</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9;The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.</license-p></license></permissions><abstract><sec><title>BACKGROUND</title><p>Antiviral drugs are widely used in populations with viral infection caused by immunologic inadequacy. Because these drugs are mainly metabolized by the kidneys, patients with renal failure undergoing renal replacement therapy are prone to drug adverse effects and poisoning. Severe neurotoxicity caused by antiviral drugs is a rare but life-threatening complication.</p></sec><sec><title>CASE SUMMARY</title><p>This study reported one male patient on peritoneal dialysis who suffered from severe mental disorders after receiving an overdose of acyclovir and valacyclovir for the treatment of herpes zoster. The literature review suggested that hemodialysis is better than peritoneal dialysis to clear acyclovir from the circulation. The patient died after his consciousness deteriorated despite peritoneal dialysis and continuous blood purification.</p></sec><sec><title>CONCLUSION</title><p>This case emphasizes cautiousness when using anti-retroviral drugs in patients with uremia. Hemodialysis is optimal method to remove the drugs.</p></sec></abstract><kwd-group><kwd>Chronic renal failure</kwd><kwd>Peritoneal dialysis</kwd><kwd>Acyclovir</kwd><kwd>Valacyclovir</kwd><kwd>Neurotoxicity</kwd><kwd>Herpes zoster</kwd><kwd>Case report</kwd></kwd-group></article-meta></front><body><p><bold>Core tip:</bold> A patient on peritoneal dialysis who received an overdose of anti-virals showed severe mental disorders. Peritoneal dialysis and continuous renal replacement therapy did not improve the symptoms. Hemodialysis is recommended to remove excess drugs.</p><sec><title>INTRODUCTION</title><p>Herpes zoster occurs upon reactivation of varicella zoster virus and is characterized by pain and blistering skin eruption with dermatomal distribution[<xref rid="B1" ref-type="bibr">1</xref>-<xref rid="B4" ref-type="bibr">4</xref>]. The occurrence of herpes zoster increases with decline in T-cell-mediated immunity, which may occur with age or immunosuppression[<xref rid="B1" ref-type="bibr">1</xref>-<xref rid="B4" ref-type="bibr">4</xref>]. The rash typically resolves in 2-4 wk, but nerve pain may continue for months to years[<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B3" ref-type="bibr">3</xref>]. Beside pain management, anti-retroviral drugs can be used in patients without response to topical anti-retroviral, age &#x02265; 50 years, moderate to severe pain, severe rash, and/or non-truncal involvement[<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B4" ref-type="bibr">4</xref>]. The common drugs include valacyclovir, acyclovir, foscarnet, and bruvudin[<xref rid="B2" ref-type="bibr">2</xref>]. Compared with acyclovir, valacyclovir has advantages such as better oral effectiveness and tolerance, high water solubility, and less adverse reactions. Valacyclovir rapidly transforms into acyclovir after entering the body. Its common side effects include nausea, vomiting, and discomfort[<xref rid="B5" ref-type="bibr">5</xref>].</p><p>One possible, albeit rare, side effect of anti-retroviral drugs is central nervous system toxicity, which has been described since the 1980s[<xref rid="B6" ref-type="bibr">6</xref>-<xref rid="B9" ref-type="bibr">9</xref>]. The symptoms in patients with previously normal brain function may include visual hallucinations, death delusion, tremor, and coma, with onset of 24-72 h after starting acyclovir[<xref rid="B8" ref-type="bibr">8</xref>]. The symptoms are possibly due to a metabolite of acyclovir that is found at high levels in the cerebrospinal fluid of patients with neuropsychiatric symptoms[<xref rid="B10" ref-type="bibr">10</xref>]. Since 90% of acyclovir is cleared by the kidneys, patients with chronic kidney disease have increased serum half-life of acyclovir[<xref rid="B11" ref-type="bibr">11</xref>]. Most patients with neuropsychiatric disorders under acyclovir treatment have renal function impairment[<xref rid="B10" ref-type="bibr">10</xref>].</p><p>We present one patient on peritoneal dialysis who suffered from severe mental disorders after taking an overdose of antiviral drugs for herpes zoster. The patient died after his consciousness did not improve after peritoneal dialysis and continuous blood purification.</p></sec><sec><title>CASE PRESENTATION</title><sec><title>Chief complaints</title><p>A 65-year-old man on peritoneal dialysis was referred to our hospital in July 2018 with complaints of blisters on the left frontal area with pain, and unstable walking and hallucinations.</p></sec><sec><title>History of present illness</title><p>The patient felt severe pain in the left frontal face, with blisters for 6 d, and was diagnosed with herpes zoster. He was given antiviral treatment with intravenous acyclovir 0.5 g qd and dexamethasone 5 mg qd to relieve pain (continuous treatment for 3 d). The dermatologist prescribed oral valacyclovir 0.3 g bid after 3 d. Nonetheless, the patient misunderstood the recommendation, and received acyclovir and valacyclovir simultaneously. After 2 d of treatment, the local facial pain was relieved, and the blisters became stable, but he became with unstable walking and involuntary shaking of the limbs, accompanied by hallucinations (irregular fluttering of objects when the eyes were closed), irritability, and lethargy. He denied fever, loss of consciousness, epilepsy, suicidal or homicidal ideation, and a sudden stop of dialysis. Before onset, the patient had mild temperament and took care of himself in the daily life.</p></sec><sec><title>History of past illness</title><p>The patient had a history of hypertension for more than 10 years, under control using nifedipine controlled release tablets 30 mg bid and valsartan 80 mg bid.</p><p>He was diagnosed with idiopathic chronic renal failure (stage 5). He had been receiving peritoneal dialysis treatment for 3 years. He was anuretic at admission using peritoneal dialysis solution with 2.5% calcium glucose 2000 mL &#x000d7; 4 bags, continuous ambulatory peritoneal dialysis (CAPD), with an ultrafiltration of 1200 mL/d.</p></sec><sec><title>Personal and family history</title><p>The patient denied any personal or family history of diseases.</p></sec><sec><title>Physical examination upon admission</title><p>On admission, the body temperature 37.2 &#x000b0;C, pulse 107 bpm, breathing 20/min, blood pressure 175/108 mmHg, intermittent mild disturbance of consciousness, and with visible scattered red blister rash in the left eyelid and left forehead, which was protruded and tender, but otherwise with normal superficial lymph nodes and cardiopulmonary examinations. Nervous system examination showed negative Pap's sign but normal muscle tension in limbs.</p></sec><sec><title>Laboratory examinations</title><p>The laboratory examinations showed: White blood cells 7.8 &#x000d7; 10<sup>9</sup>/L, hemoglobin 86 g/L, albumin 28 g/L, creatinine 1146 &#x000b5;mol/L, urea nitrogen 21.6 mmol/L, uric acid 277 &#x000b5;mol/L, potassium 4.2 mmol/L, sodium 145 mmol/ L, chlorine 100 mmol/L, PO<sub>2</sub> 43 mmHg, TCO<sub>2</sub> 24 mmol/L, glucose 4.7 mmol/L, and iPTH 313 pg/mL. Dialysis adequacy: KT/V = 1.64 (1 mo ago), Ccr= 41.4 L/wk. The electrocardiogram showed normal sinus rhythm. The lumbar puncture showed: Cerebrospinal fluid pressure 155 mmH<sub>2</sub>O, proteins 542 mg/L, glucose 4.64 mmol/L, chlorine 121.7 mmol/L (no abnormality), and negative bacteria and tuberculosis.</p></sec><sec><title>Imaging examinations</title><p>There were no obvious abnormalities in head and chest computed tomography (CT) as well as head magnetic resonance imaging (MRI).</p></sec></sec><sec><title>FINAL DIAGNOSIS</title><p>Based on the laboratory test results and imaging examinations, the differential diagnoses of cerebrovascular accidents, viral encephalitis and uremia encephalopathy were ruled out. Since he had a clear history of overdose of antiviral drugs 6 days prior to the onset of the psychiatric symptoms, the patient was finally diagnosed as mental disorders caused by antiviral drugs.</p></sec><sec><title>TREATMENT</title><p>Immediately after admission, valacyclovir was discontinued, the peritoneal fluid was increased to 5 bags/d, 2000 mL per bag, and CAPD mode, and the blood pressure was dropped to around 150-160/90 mmHg after antihypertensive treatment with Adalat 30 mg bid, valsartan 80 mg bid and perindopril 8 mg qd. After 2 d of treatment, the involuntary limb shaking was not relieved and the disturbance of consciousness progressively aggravated (drowsiness-delirium-coma). On the third day after admission (July 31, 2018), the patient's respiratory failure worsened, blood gas analysis showed: pH 7.18, PO<sub>2</sub> 81 mmHg (oxygen), and PaCO<sub>2</sub> 77 mmHg, revealing carbon dioxide retention and type 2 respiratory failure. After intubation and respiratory support, the patient was transferred to the intensive care unit (ICU) on the fourth day after admission. In the ICU, peritoneal dialysis was discontinued and continuous renal replacement therapy (CRRT) was started.</p></sec><sec><title>OUTCOME AND FOLLOW-UP</title><p>Though given positive rescue treatment, the patient&#x02019;s consciousness was not improved. The patient died 6 d after admission.</p></sec><sec><title>DISCUSSION</title><p>Herpes zoster usually develops in patients with compromised immune function. Patients on dialysis are at high risk of Herpes zoster. Both valacyclovir and acyclovir are considered to have strong inhibitory effects on types 1 and 2 herpes virus and varicella herpes virus[<xref rid="B12" ref-type="bibr">12</xref>]. Valacyclovir is a precursor of acyclovir, which is converted to acyclovir by the liver. Compared with acyclovir, it has the advantages of higher absorption rate, more better pharmacokinetics and pharmacodynamics, and lower frequency of use[<xref rid="B5" ref-type="bibr">5</xref>].</p><p>The neurotoxicity of acyclovir was reported as early as the 1980s[<xref rid="B6" ref-type="bibr">6</xref>-<xref rid="B9" ref-type="bibr">9</xref>]. The clinical manifestations include consciousness disorders and hallucinations, fantasy, insomnia, photoallergies, dysarthria, paresthesia, and coma[<xref rid="B13" ref-type="bibr">13</xref>-<xref rid="B17" ref-type="bibr">17</xref>]. If uremia patients develop neuropsychiatric symptoms during anti-retroviral treatment, it is especially important to promptly identify and discontinue the suspicious drugs. Clinicians tend to overlook drug-induced neuropsychiatric disorders. The patient had a history of excessive use of antiviral drugs and showed obvious neuropsychiatric symptoms, despite normal head CT and MRI, and lumbar puncture and cerebrospinal fluid examination. In the present report, the patient had limb shaking, visual hallucinations, and severe disturbances of consciousness, and these symptoms progressively aggravated, which is very rare.</p><p>Valacyclovir-associated neurotoxicity usually occurs within 48-72 h of treatment start, and the symptoms can be gradually relieved after the drug is discontinued for 4-14 d (Table <xref rid="T1" ref-type="table">1</xref>). For the patient in the present study, the time of onset and duration of symptoms were similar to those reported in literature[<xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B16" ref-type="bibr">16</xref>-<xref rid="B25" ref-type="bibr">25</xref>] (Table <xref rid="T1" ref-type="table">1</xref>).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>The reported cases of acyclovir/valacyclovir neurotoxicity in the literature</p></caption><table frame="hsides" rules="groups"><thead align="center"><tr><td rowspan="2" align="left" colspan="1"><bold>Author</bold></td><td rowspan="2" colspan="1"><bold>Year of publication</bold></td><td rowspan="1" colspan="1"><bold>Patient</bold></td><td rowspan="2" colspan="1"><bold>Stage of CKD</bold></td><td rowspan="2" colspan="1"><bold>Renal replacement manner</bold></td><td rowspan="2" colspan="1"><bold>Dosage (mg/d)</bold></td><td rowspan="2" colspan="1"><bold>Duration of antiviral treatment</bold></td><td rowspan="2" colspan="1"><bold>Concomi-tant medication</bold></td><td rowspan="2" colspan="1"><bold>Neuropsy-chiatric symptoms</bold></td><td rowspan="2" colspan="1"><bold>Outcome</bold></td></tr><tr><td rowspan="1" colspan="1"><bold>sex/age</bold></td></tr></thead><tbody align="center"><tr><td align="left" rowspan="1" colspan="1">Pipili et al[<xref rid="B18" ref-type="bibr">18</xref>]</td><td rowspan="1" colspan="1">2013</td><td rowspan="1" colspan="1">Female/72</td><td rowspan="1" colspan="1">ESRD</td><td rowspan="1" colspan="1">PD</td><td rowspan="1" colspan="1">Valacyclovir tablets 3 g daily for 3 d</td><td rowspan="1" colspan="1">3 d</td><td rowspan="1" colspan="1">Nifedipine, irbesartan, cinacalcet, atorvastatin, alfacalcidol</td><td rowspan="1" colspan="1">Confusion and visual hallucinations</td><td rowspan="1" colspan="1">3 d, restored after PD 6 &#x000d7; 2 L per day</td></tr><tr><td align="left" rowspan="1" colspan="1">Chaudhari et al[<xref rid="B16" ref-type="bibr">16</xref>]</td><td rowspan="1" colspan="1">2014</td><td rowspan="1" colspan="1">Male/66</td><td rowspan="1" colspan="1">ESRD</td><td rowspan="1" colspan="1">PD</td><td rowspan="1" colspan="1">Oral valacyclovir 1000 mg daily for 7 d</td><td rowspan="1" colspan="1">7 d</td><td rowspan="1" colspan="1">Simvastatin, metoprolol, sevelamer, furosemide, and glimepiride</td><td rowspan="1" colspan="1">Hallucination, insomnia, and photosensi-tivity</td><td rowspan="1" colspan="1">7 d, improved after regular regimen and hydration</td></tr><tr><td align="left" rowspan="1" colspan="1">Asahi et al[<xref rid="B17" ref-type="bibr">17</xref>]</td><td rowspan="1" colspan="1">2009</td><td rowspan="1" colspan="1">Female/78</td><td rowspan="1" colspan="1">Without previous renal failure</td><td rowspan="1" colspan="1">NO</td><td rowspan="1" colspan="1">Valacyclovir 3000 mg/d</td><td rowspan="1" colspan="1">6 d</td><td rowspan="1" colspan="1">Not mentioned</td><td rowspan="1" colspan="1">Unconsciou-sness</td><td rowspan="1" colspan="1">5 d, recovered 14 d later</td></tr><tr><td align="left" rowspan="1" colspan="1">Asahi et al[<xref rid="B17" ref-type="bibr">17</xref>]</td><td rowspan="1" colspan="1">2009</td><td rowspan="1" colspan="1">Male/73</td><td rowspan="1" colspan="1">ESRD</td><td rowspan="1" colspan="1">Hemodialysis</td><td rowspan="1" colspan="1">Valacyclovir 3000 mg/d</td><td rowspan="1" colspan="1">2 d</td><td rowspan="1" colspan="1">Not mentioned</td><td rowspan="1" colspan="1">Confusion, hallucination</td><td rowspan="1" colspan="1">2 d, completely recovered 3 d later</td></tr><tr><td align="left" rowspan="1" colspan="1">Singh et al[<xref rid="B19" ref-type="bibr">19</xref>]</td><td rowspan="1" colspan="1">2014</td><td rowspan="1" colspan="1">Female/58</td><td rowspan="1" colspan="1">ESRD</td><td rowspan="1" colspan="1">HD</td><td rowspan="1" colspan="1">Valacyclovir 500 mg/d</td><td rowspan="1" colspan="1">2 d</td><td rowspan="1" colspan="1">Not mentioned</td><td rowspan="1" colspan="1">Altered sensorium, irritability, drowsiness, confusion</td><td rowspan="1" colspan="1">2 d, completely recovered 5 d later</td></tr><tr><td align="left" rowspan="1" colspan="1">Kambham-pati et al[<xref rid="B20" ref-type="bibr">20</xref>]</td><td rowspan="1" colspan="1">2011</td><td rowspan="1" colspan="1">Female/49</td><td rowspan="1" colspan="1">ESRD</td><td rowspan="1" colspan="1">Maintenance hemodialysis</td><td rowspan="1" colspan="1">Valacyclovir 1000 mg three times a day</td><td rowspan="1" colspan="1">2 d</td><td rowspan="1" colspan="1">Not mentioned</td><td rowspan="1" colspan="1">Disoriented, confused, agitated, hallucinating, delirious, incoherent</td><td rowspan="1" colspan="1">1 d, 4000 mg, completely recovered after second session of hemodialysis</td></tr><tr><td align="left" rowspan="1" colspan="1">Prasad et al[<xref rid="B14" ref-type="bibr">14</xref>]</td><td rowspan="1" colspan="1">2017</td><td rowspan="1" colspan="1">Female/57</td><td rowspan="1" colspan="1">ESRD</td><td rowspan="1" colspan="1">PD</td><td rowspan="1" colspan="1">1000&#x02009;mg three times per day of valacyclovir</td><td rowspan="1" colspan="1">3 d</td><td rowspan="1" colspan="1">Not mentioned</td><td rowspan="1" colspan="1">Confusion and altered sensorium</td><td rowspan="1" colspan="1">1 day, completely recovered 24&#x02009;h later</td></tr><tr><td align="left" rowspan="1" colspan="1">Izzedine et al[<xref rid="B21" ref-type="bibr">21</xref>]</td><td rowspan="1" colspan="1">2001</td><td rowspan="1" colspan="1">Female/60</td><td rowspan="1" colspan="1">ESRD</td><td rowspan="1" colspan="1">PD</td><td rowspan="1" colspan="1">Valacyclovir 500 mg daily</td><td rowspan="1" colspan="1">Reduced 500 mg of valacyclovir every 2 d</td><td rowspan="1" colspan="1">Not mentioned</td><td rowspan="1" colspan="1">Disorientated with ocular and auditory hallucinations and loss of decorum without torpor or coma.</td><td rowspan="1" colspan="1">3 d, recovered 48 h later</td></tr><tr><td align="left" rowspan="1" colspan="1">Strumia et al[<xref rid="B22" ref-type="bibr">22</xref>]</td><td rowspan="1" colspan="1">2004</td><td rowspan="1" colspan="1">Male/81</td><td rowspan="1" colspan="1">ESRD</td><td rowspan="1" colspan="1">Hemodialysis</td><td rowspan="1" colspan="1">Oral valacyclovir 1000 mg every 8 h then intravenous acyclovir in full dosage</td><td rowspan="1" colspan="1">3 d</td><td rowspan="1" colspan="1">Not mentioned</td><td rowspan="1" colspan="1">Visual hallucination, confusion and disorientation</td><td rowspan="1" colspan="1">3 daysd completely recovered 6 d later</td></tr><tr><td align="left" rowspan="1" colspan="1">Linssen-Schuurmans et al[<xref rid="B23" ref-type="bibr">23</xref>]</td><td rowspan="1" colspan="1">1998</td><td rowspan="1" colspan="1">Male/58</td><td rowspan="1" colspan="1">CKD</td><td rowspan="1" colspan="1">Intermittent hemodialysis twice a week</td><td rowspan="1" colspan="1">Valacyclovir 3 g/d</td><td rowspan="1" colspan="1">2 d</td><td rowspan="1" colspan="1">Not mentioned</td><td rowspan="1" colspan="1">Dizziness, hallucinations, loss of decorum, disoriented, slurred speech</td><td rowspan="1" colspan="1">1 d, complete recovery</td></tr><tr><td align="left" rowspan="1" colspan="1">Takayanagi et al[<xref rid="B24" ref-type="bibr">24</xref>]</td><td rowspan="1" colspan="1">2010</td><td rowspan="1" colspan="1">Male/67</td><td rowspan="1" colspan="1">ESRD</td><td rowspan="1" colspan="1">PD</td><td rowspan="1" colspan="1">Valacyclovir, 1 g/d</td><td rowspan="1" colspan="1">5 d</td><td rowspan="1" colspan="1">Not mentioned</td><td rowspan="1" colspan="1">Hallucina-tions</td><td rowspan="1" colspan="1">7 d, complete recovery</td></tr><tr><td align="left" rowspan="1" colspan="1">Sadjadi et al[<xref rid="B25" ref-type="bibr">25</xref>]</td><td rowspan="1" colspan="1">2018</td><td rowspan="1" colspan="1">Male/80</td><td rowspan="1" colspan="1">ESRD</td><td rowspan="1" colspan="1">PD</td><td rowspan="1" colspan="1">Acyclovir 5 mg/kg intravenously, followed by oral acyclobir 400 mg/d</td><td rowspan="1" colspan="1">3 d</td><td rowspan="1" colspan="1">Not mentioned</td><td rowspan="1" colspan="1">Confusion, delusion, disorientation, restlessness, visual hallucinations, seizures</td><td rowspan="1" colspan="1">2 d, complete recovery</td></tr></tbody></table><table-wrap-foot><fn><p>CKD: Chronic kidney disease; ESRD: End-stage renal disease; PD: Peritoneal dialysis.</p></fn></table-wrap-foot></table-wrap><p>Since acyclovir is mainly cleared by the kidneys, it is a consensus to reduce its dose in patients with renal failure[<xref rid="B25" ref-type="bibr">25</xref>]. The dose is mainly determined by a combination of factors such as different methods of dialysis, residual renal function, hydration, and age. The dose of drug used in many cases of neurotoxicity is often greater than the recommended dose[<xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B24" ref-type="bibr">24</xref>]. It is generally believed that a concentration of acyclovir of 2.5-4.5 &#x000b5;g/mL[<xref rid="B26" ref-type="bibr">26</xref>] or a concentration of its main metabolite, carboxymethoxy methylguanine, above 10.8 &#x000b5;mol/L[<xref rid="B10" ref-type="bibr">10</xref>] in plasma leads to neurotoxicity. Nevertheless, there is still no consensus on the specific numerical reference range of therapeutic and toxic doses of such drugs, and it is difficult to measure the drug levels in clinical practice.</p><p>In the case reported here, increasing the dose of peritoneal dialysis and retention time still could not alleviate the clinical symptoms. Acyclovir and valacyclovir are both soluble and low-protein-bound drugs. In terms of the effectiveness of valacyclovir, a single hemodialysis for 6 h can remove about 60% of the drug, while it is considered to have poor clearance by peritoneal dialysis. On the other hand, case reports suggested that peritoneal dialysis with continuous perfusion of super-dose peritoneal dialysis solution can promote the clearance of valacyclovir[<xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B21" ref-type="bibr">21</xref>,<xref rid="B24" ref-type="bibr">24</xref>,<xref rid="B27" ref-type="bibr">27</xref>]. Studies have shown that in patients with normal renal function, 89% of valacyclovir can be cleared from the urine in the form of acyclovir after 2.5-3.3 h, while the half-life of the drug is extended to 14-20 h in patients receiving CAPD for uremia (4 &#x000d7; 2 L exchange dose), and only 5.27 mL/min (0.355 L/h/1.73 m<sup>2</sup>) can be cleared by peritoneal dialysis[<xref rid="B21" ref-type="bibr">21</xref>,<xref rid="B27" ref-type="bibr">27</xref>]. After a 6-h hemodialysis, the hemodialysis clearance rate of acyclovir is up to 113 mL/min and the plasma drug concentration can be reduced by 61.6%. Therefore, hemodialysis is at least 20 times better than peritoneal dialysis in terms of clearance effect. Based on the large differences in clearance rates between the two dialysis methods, it is suggested to switch peritoneal dialysis to hemodialysis to increase the effect of drug clearance[<xref rid="B20" ref-type="bibr">20</xref>,<xref rid="B24" ref-type="bibr">24</xref>,<xref rid="B28" ref-type="bibr">28</xref>]. Nevertheless, when neurotoxicity occurs, the expected improvement of neurotoxicity by hemodialysis may be delayed, even for a few days. Kageyama et al[<xref rid="B29" ref-type="bibr">29</xref>] reported a 75-year-old hemodialysis male who presented with hallucinations, dysarthria, and psychotic symptoms after intravenous acyclovir with reduced dose, which further indicates that the dose adjustment of these drugs is difficult and needs to be comprehensively individualized. CRRT has a good effect on clearing drugs with middle-and-large molecular weight or high protein binding rate. Meanwhile, valacyclovir and acyclovir are soluble and have a low protein binding rate, but there is a lack of literature on the efficacy of CRRT in clearing acyclovir and valacyclovir.</p></sec><sec><title>CONCLUSION</title><p>In summary, clinicians need to be extra cautious when applying antiviral drugs in patients with renal failure. They need to be alert to the possible serious neuropsychiatric symptoms, need to adjust dose according to the level of renal function, pay attention to treatment course and hydration, be fully aware of the possible neurotoxicity caused by these drugs, and be aware of the good prognosis after early identification and active intervention. In the meantime, since the clearance rate of these drugs is low when using peritoneal dialysis, these patients should be switched to hemodialysis.</p></sec></body><back><fn-group><fn><p>Informed consent statement: Consent was obtained from relatives of the patient for publication of this report and any accompanying images.</p></fn><fn fn-type="COI-statement"><p>Conflict-of-interest statement: The authors declare that they have no conflicts of interest.</p></fn><fn><p>CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).</p></fn><fn><p>Manuscript source: Unsolicited manuscript</p></fn><fn><p>Peer-review started: June 4, 2019</p></fn><fn><p>First decision: August 1, 2019</p></fn><fn><p>Article in press: September 11, 2019</p></fn><fn><p>Specialty type: Medicine, research and experimental</p></fn><fn><p>Country of origin: China</p></fn><fn><p>Peer-review report classification</p></fn><fn><p>Grade A (Excellent): 0</p></fn><fn><p>Grade B (Very good): 0</p></fn><fn><p>Grade C (Good): C</p></fn><fn><p>Grade D (Fair): 0</p></fn><fn><p>Grade E (Poor): 0</p></fn><fn><p>P-Reviewer: Hatipoglu S S-Editor: Wang JL L-Editor: Ma JY E-Editor: Qi LL</p></fn></fn-group><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sampathkumar</surname><given-names>P</given-names></name><name><surname>Drage</surname><given-names>LA</given-names></name><name><surname>Martin</surname><given-names>DP</given-names></name></person-group><article-title>Herpes zoster (shingles) and postherpetic neuralgia</article-title><source>Mayo Clin Proc</source><year>2009</year><volume>84</volume><fpage>274</fpage><lpage>280</lpage><pub-id pub-id-type="pmid">19252116</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>JI</given-names></name></person-group><article-title>Clinical practice: Herpes zoster</article-title><source>N Engl J Med</source><year>2013</year><volume>369</volume><fpage>255</fpage><lpage>263</lpage><pub-id pub-id-type="pmid">23863052</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>JF</given-names></name></person-group><article-title>In the clinic. Herpes zoster</article-title><source>Ann Intern Med</source><year>2011</year><volume>154</volume><fpage>ITC31</fpage><lpage>15; quiz ITC316</lpage><pub-id pub-id-type="pmid">21357905</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dworkin</surname><given-names>RH</given-names></name><name><surname>Johnson</surname><given-names>RW</given-names></name><name><surname>Breuer</surname><given-names>J</given-names></name><name><surname>Gnann</surname><given-names>JW</given-names></name><name><surname>Levin</surname><given-names>MJ</given-names></name><name><surname>Backonja</surname><given-names>M</given-names></name><name><surname>Betts</surname><given-names>RF</given-names></name><name><surname>Gershon</surname><given-names>AA</given-names></name><name><surname>Haanpaa</surname><given-names>ML</given-names></name><name><surname>McKendrick</surname><given-names>MW</given-names></name><name><surname>Nurmikko</surname><given-names>TJ</given-names></name><name><surname>Oaklander</surname><given-names>AL</given-names></name><name><surname>Oxman</surname><given-names>MN</given-names></name><name><surname>Pavan-Langston</surname><given-names>D</given-names></name><name><surname>Petersen</surname><given-names>KL</given-names></name><name><surname>Rowbotham</surname><given-names>MC</given-names></name><name><surname>Schmader</surname><given-names>KE</given-names></name><name><surname>Stacey</surname><given-names>BR</given-names></name><name><surname>Tyring</surname><given-names>SK</given-names></name><name><surname>van Wijck</surname><given-names>AJ</given-names></name><name><surname>Wallace</surname><given-names>MS</given-names></name><name><surname>Wassilew</surname><given-names>SW</given-names></name><name><surname>Whitley</surname><given-names>RJ</given-names></name></person-group><article-title>Recommendations for the management of herpes zoster</article-title><source>Clin Infect Dis</source><year>2007</year><volume>44 Suppl 1</volume><fpage>S1</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">17143845</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cernik</surname><given-names>C</given-names></name><name><surname>Gallina</surname><given-names>K</given-names></name><name><surname>Brodell</surname><given-names>RT</given-names></name></person-group><article-title>The treatment of herpes simplex infections: an evidence-based review</article-title><source>Arch Intern Med</source><year>2008</year><volume>168</volume><fpage>1137</fpage><lpage>1144</lpage><pub-id pub-id-type="pmid">18541820</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wade</surname><given-names>JC</given-names></name><name><surname>Meyers</surname><given-names>JD</given-names></name></person-group><article-title>Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation</article-title><source>Ann Intern Med</source><year>1983</year><volume>98</volume><fpage>921</fpage><lpage>925</lpage><pub-id pub-id-type="pmid">6305245</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>SM</given-names></name><name><surname>Minkove</surname><given-names>JA</given-names></name><name><surname>Zebley</surname><given-names>JW</given-names><suffix>3rd</suffix></name><name><surname>Mulholland</surname><given-names>JH</given-names></name></person-group><article-title>Severe but reversible neurotoxicity from acyclovir</article-title><source>Ann Intern Med</source><year>1984</year><volume>100</volume><fpage>920</fpage></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomson</surname><given-names>CR</given-names></name><name><surname>Goodship</surname><given-names>TH</given-names></name><name><surname>Rodger</surname><given-names>RS</given-names></name></person-group><article-title>Psychiatric side-effects of acyclovir in patients with chronic renal failure</article-title><source>Lancet</source><year>1985</year><volume>2</volume><fpage>385</fpage><lpage>386</lpage></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vartian</surname><given-names>CV</given-names></name><name><surname>Shlaes</surname><given-names>DM</given-names></name></person-group><article-title>Intravenous acyclovir and neurologic effects</article-title><source>Ann Intern Med</source><year>1983</year><volume>99</volume><fpage>568</fpage></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Helld&#x000e9;n</surname><given-names>A</given-names></name><name><surname>Odar-Cederl&#x000f6;f</surname><given-names>I</given-names></name><name><surname>Diener</surname><given-names>P</given-names></name><name><surname>Barkholt</surname><given-names>L</given-names></name><name><surname>Medin</surname><given-names>C</given-names></name><name><surname>Svensson</surname><given-names>JO</given-names></name><name><surname>S&#x000e4;we</surname><given-names>J</given-names></name><name><surname>St&#x000e5;hle</surname><given-names>L</given-names></name></person-group><article-title>High serum concentrations of the acyclovir main metabolite 9-carboxymethoxymethylguanine in renal failure patients with acyclovir-related neuropsychiatric side effects: an observational study</article-title><source>Nephrol Dial Transplant</source><year>2003</year><volume>18</volume><fpage>1135</fpage><lpage>1141</lpage><pub-id pub-id-type="pmid">12748346</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haefeli</surname><given-names>WE</given-names></name><name><surname>Schoenenberger</surname><given-names>RA</given-names></name><name><surname>Weiss</surname><given-names>P</given-names></name><name><surname>Ritz</surname><given-names>RF</given-names></name></person-group><article-title>Acyclovir-induced neurotoxicity: concentration-side effect relationship in acyclovir overdose</article-title><source>Am J Med</source><year>1993</year><volume>94</volume><fpage>212</fpage><lpage>215</lpage><pub-id pub-id-type="pmid">8430717</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>WR</given-names></name><name><surname>Lin</surname><given-names>HH</given-names></name><name><surname>Lee</surname><given-names>SS</given-names></name><name><surname>Tsai</surname><given-names>HC</given-names></name><name><surname>Huang</surname><given-names>CK</given-names></name><name><surname>Wann</surname><given-names>SR</given-names></name><name><surname>Chen</surname><given-names>YS</given-names></name><name><surname>Chiang</surname><given-names>SC</given-names></name><name><surname>Yen</surname><given-names>MY</given-names></name><name><surname>Liu</surname><given-names>YC</given-names></name></person-group><article-title>Comparative study of the efficacy and safety of valaciclovir versus acyclovir in the treatment of herpes zoster</article-title><source>J Microbiol Immunol Infect</source><year>2001</year><volume>34</volume><fpage>138</fpage><lpage>142</lpage><pub-id pub-id-type="pmid">11456360</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okada</surname><given-names>T</given-names></name><name><surname>Nakao</surname><given-names>T</given-names></name><name><surname>Matsumoto</surname><given-names>H</given-names></name><name><surname>Nagaoka</surname><given-names>Y</given-names></name><name><surname>Iwasawa</surname><given-names>H</given-names></name><name><surname>Nanri</surname><given-names>K</given-names></name><name><surname>Yamazaki</surname><given-names>T</given-names></name></person-group><article-title>Valacyclovir neurotoxicity in a patient with end-stage renal disease treated with continuous ambulatory peritoneal dialysis</article-title><source>Clin Nephrol</source><year>2002</year><volume>58</volume><fpage>168</fpage><lpage>170</lpage><pub-id pub-id-type="pmid">12227692</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prasad</surname><given-names>B</given-names></name><name><surname>McIsaac</surname><given-names>M</given-names></name><name><surname>Toppings</surname><given-names>J</given-names></name></person-group><article-title>Valacyclovir-associated neurotoxicity treated with intensification of peritoneal dialysis</article-title><source>BMJ Case Rep</source><year>2017</year><volume>2017</volume><fpage>bcr</fpage><lpage>2017-220678</lpage></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olin</surname><given-names>JL</given-names></name><name><surname>Gugliotta</surname><given-names>JL</given-names></name></person-group><article-title>Possible valacyclovir-related neurotoxicity and aseptic meningitis</article-title><source>Ann Pharmacother</source><year>2003</year><volume>37</volume><fpage>1814</fpage><lpage>1817</lpage><pub-id pub-id-type="pmid">14632597</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaudhari</surname><given-names>D</given-names></name><name><surname>Ginn</surname><given-names>D</given-names></name></person-group><article-title>Valacyclovir-associated neurotoxicity in peritoneal dialysis patients</article-title><source>Am J Ther</source><year>2014</year><volume>21</volume><fpage>e215</fpage><lpage>e217</lpage><pub-id pub-id-type="pmid">23528373</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asahi</surname><given-names>T</given-names></name><name><surname>Tsutsui</surname><given-names>M</given-names></name><name><surname>Wakasugi</surname><given-names>M</given-names></name><name><surname>Tange</surname><given-names>D</given-names></name><name><surname>Takahashi</surname><given-names>C</given-names></name><name><surname>Tokui</surname><given-names>K</given-names></name><name><surname>Okazawa</surname><given-names>S</given-names></name><name><surname>Okudera</surname><given-names>H</given-names></name></person-group><article-title>Valacyclovir neurotoxicity: clinical experience and review of the literature</article-title><source>Eur J Neurol</source><year>2009</year><volume>16</volume><fpage>457</fpage><lpage>460</lpage><pub-id pub-id-type="pmid">19187258</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pipili</surname><given-names>C</given-names></name><name><surname>Pantelias</surname><given-names>K</given-names></name><name><surname>Deda</surname><given-names>E</given-names></name><name><surname>Tsiamalos</surname><given-names>P</given-names></name><name><surname>Kostis</surname><given-names>E</given-names></name><name><surname>Grapsa</surname><given-names>E</given-names></name></person-group><article-title>Intensification of peritoneal dialysis improves valacyclovir neurotoxicity</article-title><source>Ren Fail</source><year>2013</year><volume>35</volume><fpage>289</fpage><lpage>290</lpage><pub-id pub-id-type="pmid">23176110</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>NP</given-names></name><name><surname>Shah</surname><given-names>HR</given-names></name><name><surname>Aggarwal</surname><given-names>N</given-names></name><name><surname>Jha</surname><given-names>LK</given-names></name><name><surname>Behura</surname><given-names>S</given-names></name></person-group><article-title>Valacyclovir associated neurotoxicity in a patient on dialysis</article-title><source>Indian J Nephrol</source><year>2014</year><volume>24</volume><fpage>128</fpage><lpage>129</lpage><pub-id pub-id-type="pmid">24701050</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kambhampati</surname><given-names>G</given-names></name><name><surname>Pakkivenkata</surname><given-names>U</given-names></name><name><surname>Kazory</surname><given-names>A</given-names></name></person-group><article-title>Valacyclovir neurotoxicity can be effectively managed by hemodialysis</article-title><source>Eur J Neurol</source><year>2011</year><volume>18</volume><fpage>e33</fpage><pub-id pub-id-type="pmid">21087359</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Izzedine</surname><given-names>H</given-names></name><name><surname>Mercadal</surname><given-names>L</given-names></name><name><surname>Aymard</surname><given-names>G</given-names></name><name><surname>Launay-Vacher</surname><given-names>V</given-names></name><name><surname>Martinez</surname><given-names>V</given-names></name><name><surname>Issad</surname><given-names>B</given-names></name><name><surname>Deray</surname><given-names>G</given-names></name></person-group><article-title>Neurotoxicity of valacyclovir in peritoneal dialysis: a pharmacokinetic study</article-title><source>Am J Nephrol</source><year>2001</year><volume>21</volume><fpage>162</fpage><lpage>164</lpage><pub-id pub-id-type="pmid">11359026</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strumia</surname><given-names>S</given-names></name><name><surname>De Mitri</surname><given-names>P</given-names></name><name><surname>Bionda</surname><given-names>E</given-names></name></person-group><article-title>Neurotoxicity of acyclovir and valacyclovir in a hemodialyzed patient</article-title><source>Eur J Neurol</source><year>2004</year><volume>11</volume><fpage>68</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">14692893</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linssen-Schuurmans</surname><given-names>CD</given-names></name><name><surname>van Kan</surname><given-names>EJ</given-names></name><name><surname>Feith</surname><given-names>GW</given-names></name><name><surname>Uges</surname><given-names>DR</given-names></name></person-group><article-title>Neurotoxicity caused by valacyclovir in a patient on hemodialysis</article-title><source>Ther Drug Monit</source><year>1998</year><volume>20</volume><fpage>385</fpage><lpage>386</lpage><pub-id pub-id-type="pmid">9712461</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takayanagi</surname><given-names>A</given-names></name><name><surname>Maehana</surname><given-names>T</given-names></name><name><surname>Kyoda</surname><given-names>Y</given-names></name><name><surname>Yanase</surname><given-names>M</given-names></name></person-group><article-title>[Neurotoxicity of valacyclovir in a peritoneal dialysis patient]</article-title><source>Hinyokika Kiyo</source><year>2010</year><volume>56</volume><fpage>617</fpage><lpage>619</lpage><pub-id pub-id-type="pmid">21187705</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadjadi</surname><given-names>SA</given-names></name><name><surname>Regmi</surname><given-names>S</given-names></name><name><surname>Chau</surname><given-names>T</given-names></name></person-group><article-title>Acyclovir Neurotoxicity in a Peritoneal Dialysis Patient: Report of a Case and Review of the Pharmacokinetics of Acyclovir</article-title><source>Am J Case Rep</source><year>2018</year><volume>19</volume><fpage>1459</fpage><lpage>1462</lpage><pub-id pub-id-type="pmid">30531673</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feldman</surname><given-names>S</given-names></name><name><surname>Rodman</surname><given-names>J</given-names></name><name><surname>Gregory</surname><given-names>B</given-names></name></person-group><article-title>Excessive serum concentrations of acyclovir and neurotoxicity</article-title><source>J Infect Dis</source><year>1988</year><volume>157</volume><fpage>385</fpage><lpage>388</lpage><pub-id pub-id-type="pmid">3335815</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stathoulopoulou</surname><given-names>F</given-names></name><name><surname>Dhillon</surname><given-names>S</given-names></name><name><surname>Thodis</surname><given-names>H</given-names></name><name><surname>Stathakis</surname><given-names>C</given-names></name><name><surname>Vargemezis</surname><given-names>V</given-names></name></person-group><article-title>Evaluation of valaciclovir dosage reduction in continuous ambulatory peritoneal dialysis patients</article-title><source>Nephron</source><year>2002</year><volume>91</volume><fpage>164</fpage><lpage>166</lpage><pub-id pub-id-type="pmid">12021536</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takayanagi</surname><given-names>A</given-names></name><name><surname>Hashimoto</surname><given-names>J</given-names></name><name><surname>Adachi</surname><given-names>H</given-names></name><name><surname>Horita</surname><given-names>H</given-names></name></person-group><article-title>Two patients with neurotoxicity caused by over-dose of antiviral drugs during hemodialysis therapy</article-title><source>Jpn J Clin Neurol</source><year>2006</year><volume>60</volume><fpage>581</fpage><lpage>583</lpage></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kageyama</surname><given-names>R</given-names></name><name><surname>Hashizume</surname><given-names>H</given-names></name></person-group><article-title>Neurotoxicity induced by the recommended acyclovir dosing in a dialysis patient with herpes zoster: A case letter</article-title><source>J Dermatol</source><year>2016</year><volume>43</volume><fpage>339</fpage><lpage>340</lpage><pub-id pub-id-type="pmid">26589129</pub-id></element-citation></ref></ref-list></back></article>